{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:33:32Z","timestamp":1794346412682,"version":"4.9.0"},"reference-count":161,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) is considered a distinct IBD phenotype, with probably a distinct pathogenesis according to genome-wide association studies and mucosal immunology and microbiome studies. Management of IBD in patients with PSC presents with specific monitoring and therapeutic challenges. Both IBD-related and treatment-related complications have to be carefully considered in the context of hepatobiliary disease, end-stage liver disease, and liver transplant recipients. Standard IBD drug therapies are generally effective and well-tolerated in PSC-IBD, both pre- and post-liver transplantation. However, evidence of direct benefit on PSC progression is limited and largely based on surrogate endpoints such as alkaline phosphatase reduction. Vedolizumab and adalimumab have shown modest biochemical improvements in selected cohorts, although no therapy has demonstrated consistent disease-modifying effects on PSC. Based on current available data, vancomycin seems promising to improve IBD and PSC outcomes. In patients with an indication for colectomy, counseling on functional outcome in general and on disease-specific risks of recurrent intestinal inflammation, neoplasia, and PSC progression is warranted. Immunosuppressive regimens posttransplant and persistent intestinal inflammation influence graft survival and PSC recurrence. Thus, management in patients with PSC and IBD requires a tailored, risk-adapted approach, integrating control of intestinal inflammation, hepatobiliary monitoring, and cancer surveillance. This contemporary review aimede to elucidate the current understanding regarding the efficacy and safety of medical and surgical therapies used for IBD in light of the pre- and posttransplant course of patients with PSC-IBD.<\/jats:p>","DOI":"10.1097\/tp.0000000000005607","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:00:10Z","timestamp":1769626810000},"page":"e543-e553","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Management of Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis Pre- and Post-liver Transplantation"],"prefix":"10.1097","volume":"110","author":[{"given":"Marin J.","family":"de Jong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauranne A.A.P.","family":"Derikx","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Darwish Murad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan J.","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie C.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"R1-20260217","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study.","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R2-20260217","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014a comprehensive review.","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20260217","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies.","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20260217","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"R5-20260217","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland.","volume":"55","author":"Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"R6-20260217","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"R7-20260217","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"R8-20260217","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20260217","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2019.05.006","article-title":"Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.","volume":"71","author":"de Krijger","year":"2019","journal-title":"J Hepatol"},{"key":"R10-20260217","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bpg.2011.10.009","article-title":"Pathogenesis of primary sclerosing cholangitis.","volume":"25","author":"Pollheimer","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R11-20260217","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.31311","article-title":"The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications.","volume":"72","author":"Dean","year":"2020","journal-title":"Hepatology"},{"key":"R12-20260217","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J Hepatol"},{"key":"R13-20260217","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/liv.15339","article-title":"Prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review and meta-analysis.","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int"},{"key":"R14-20260217","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis.","volume":"102","author":"Kaplan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R15-20260217","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography.","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"key":"R16-20260217","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon.","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-20260217","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/00365521.2012.685754","article-title":"Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.","volume":"47","author":"Jorgensen","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"R18-20260217","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/PAS.0b013e318196d018","article-title":"Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study.","volume":"33","author":"Joo","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R19-20260217","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"R20-20260217","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","article-title":"Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.","volume":"52","author":"Fevery","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R21-20260217","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.","volume":"24","author":"Mouchli","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20260217","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R23-20260217","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis.","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"R24-20260217","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO guidelines on inflammatory bowel disease and malignancies.","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R25-20260217","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.3745","article-title":"Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.","volume":"49","author":"Ji","year":"2017","journal-title":"Nat Genet"},{"key":"R26-20260217","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"R27-20260217","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ecco-jcc\/jjx050","article-title":"Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease.","volume":"11","author":"Gwela","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R28-20260217","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"R29-20260217","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ecco-jcc\/jju023","article-title":"The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.","volume":"9","author":"Rossen","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R30-20260217","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"R31-20260217","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.","volume":"21","author":"de Vries","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R32-20260217","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"R33-20260217","doi-asserted-by":"crossref","first-page":"i499","DOI":"10.1093\/ecco-jcc\/jjad212.0318","article-title":"Cumulative inflammatory burden as a risk factor for colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis: a multi-center case-control study.","volume":"18","author":"van Lierop","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R34-20260217","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis.","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"R35-20260217","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment.","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R36-20260217","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13516","article-title":"Patients with large-duct primary sclerosing cholangitis and Crohn\u2019s disease have a better outcome than those with ulcerative colitis, or without IBD.","volume":"43","author":"Fevery","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20260217","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","article-title":"Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.","volume":"124","author":"Pardi","year":"2003","journal-title":"Gastroenterology"},{"key":"R38-20260217","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","article-title":"Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.","volume":"134","author":"Tung","year":"2001","journal-title":"Ann Intern Med"},{"key":"R39-20260217","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R40-20260217","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2036.2005.02650.x","article-title":"The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.","volume":"22","author":"Wolf","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-20260217","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2011.04966.x","article-title":"High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.","volume":"35","author":"Lindstrom","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-20260217","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.","volume":"58","author":"Hansen","year":"2013","journal-title":"Dig Dis Sci"},{"key":"R43-20260217","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R44-20260217","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"R45-20260217","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study.","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R46-20260217","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study.","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"R47-20260217","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis.","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"R48-20260217","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/ibd\/izz027","article-title":"Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis.","volume":"25","author":"Dao","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R49-20260217","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"key":"R50-20260217","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ibd\/izad040","article-title":"Oral vancomycin induced and maintained clinical and endoscopic remission in ulcerative colitis and primary sclerosing cholangitis post-liver transplantation.","volume":"29","author":"Almomen","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R51-20260217","doi-asserted-by":"crossref","first-page":"jjae189","DOI":"10.1093\/ecco-jcc\/jjae189","article-title":"Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures.","volume":"19","author":"Quraishi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"R52-20260217","doi-asserted-by":"crossref","first-page":"17562848241312766","DOI":"10.1177\/17562848241312766","article-title":"Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.","volume":"18","author":"Sannaa","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"R53-20260217","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/ibd\/izy106","article-title":"The natural history of newly diagnosed ulcerative colitis in patients with concomitant primary sclerosing cholangitis.","volume":"24","author":"Khan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R54-20260217","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/ibd\/izae257","article-title":"The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review.","volume":"31","author":"Arbabzada","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R55-20260217","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.","volume":"2016","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R56-20260217","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.","volume":"4","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20260217","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.18632\/oncotarget.13715","article-title":"Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.","volume":"8","author":"Qiu","year":"2017","journal-title":"Oncotarget"},{"key":"R58-20260217","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/apt.13897","article-title":"The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.","volume":"45","author":"Carrat","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R59-20260217","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.12469","article-title":"The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.","volume":"38","author":"Eaton","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R60-20260217","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ibd.21692","article-title":"Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis.","volume":"18","author":"Hanouneh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R61-20260217","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"R62-20260217","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ibd.21083","article-title":"Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis.","volume":"16","author":"Chebli","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"R63-20260217","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn\u2019s disease with 6-mercaptopurine. A long-term, randomized, double-blind study.","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"R64-20260217","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management.","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R65-20260217","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/apt.17123","article-title":"Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.","volume":"56","author":"Biron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R66-20260217","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cgh.2016.07.032","article-title":"No evidence that azathioprine increases risk of cholangiocarcinoma in patients with primary sclerosing cholangitis.","volume":"14","author":"Zenouzi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R67-20260217","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R68-20260217","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis.","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R69-20260217","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ecco-jcc\/jjx057","article-title":"Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis.","volume":"11","author":"Westerouen van Meeteren","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R70-20260217","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series.","volume":"50","author":"Altwegg","year":"2018","journal-title":"Dig Liver Dis"},{"key":"R71-20260217","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis.","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R72-20260217","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"R73-20260217","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis.","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R74-20260217","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"R75-20260217","first-page":"412","article-title":"Long-term efficacy of vedolizumab for crohn\u2019s disease.","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R76-20260217","doi-asserted-by":"crossref","first-page":"E39","DOI":"10.1097\/MIB.0000000000000906","article-title":"Vedolizumab in inflammatory bowel disease associated with autoimmune liver disease pre- and postliver transplantation: a case series.","volume":"22","author":"Lim","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R77-20260217","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cgh.2019.07.020","article-title":"All that glitters is not gold in vedolizumab therapy for patients with inflammatory bowel diseases and primary sclerosing cholangitis.","volume":"18","author":"Roda","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R78-20260217","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R79-20260217","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases.","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R80-20260217","doi-asserted-by":"crossref","first-page":"bcr","DOI":"10.1136\/bcr-2017-220351","article-title":"Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis.","volume":"2017","author":"Westerveld","year":"2017","journal-title":"BMJ Case Rep"},{"key":"R81-20260217","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study.","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R82-20260217","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MEG.0000000000002076","article-title":"Review article: safety of new biologic agents for inflammatory bowel disease in the liver.","volume":"33","author":"Magri","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R83-20260217","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/2050640619858050","article-title":"Safety of vedolizumab in liver transplant recipients: a systematic review.","volume":"7","author":"Spadaccini","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"R84-20260217","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"R85-20260217","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"R86-20260217","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis.","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"R87-20260217","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R88-20260217","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial.","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"R89-20260217","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R90-20260217","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn\u2019s disease.","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"R91-20260217","doi-asserted-by":"crossref","first-page":"108517","DOI":"10.1016\/j.intimp.2022.108517","article-title":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: a literature review.","volume":"105","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R92-20260217","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study.","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R93-20260217","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjaa032","article-title":"Use of tofacitinib for ulcerative colitis in a liver transplant patient.","volume":"15","author":"Meunier","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R94-20260217","first-page":"5257","article-title":"Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta.","volume":"55","author":"Wali","year":"1995","journal-title":"Cancer Res"},{"key":"R95-20260217","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12664-024-01537-x","article-title":"Antibiotics for inflammatory bowel disease: current status.","volume":"43","author":"Jha","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"R96-20260217","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.14309\/00000434-201802001-00020","article-title":"Therapeutic effect of vancomycin in UC patients associated with PSC: case series: P-020.","volume":"113","author":"Fahad","year":"2018","journal-title":"Official J Am College Gastroenterol | ACG"},{"key":"R97-20260217","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ibd.21699","article-title":"Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients.","volume":"18","author":"Jorgensen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R98-20260217","article-title":"5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.","volume":"72","author":"Adamowicz","year":"2021","journal-title":"J Physiol Pharmacol"},{"key":"R99-20260217","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11901-019-00456-2","article-title":"The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis.","volume":"18","author":"Lynch","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"R100-20260217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00281-022-00910-2","article-title":"TNF in the liver: targeting a central player in inflammation.","volume":"44","author":"Tiegs","year":"2022","journal-title":"Semin Immunopathol"},{"key":"R101-20260217","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1440-1827.2002.01365.x","article-title":"Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn\u2019s disease.","volume":"52","author":"Arihiro","year":"2002","journal-title":"Pathol Int"},{"key":"R102-20260217","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn\u2019s disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"R103-20260217","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R104-20260217","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ecco-jcc\/jjv109","article-title":"Ustekinumab is effective and safe in the treatment of Crohn\u2019s disease refractory to anti-TNFalpha in an orthotopic liver transplant patient.","volume":"9","author":"Martinez-Montiel","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R105-20260217","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ecco-jcc\/jjaa062","article-title":"Ustekinumab is a safe and effective biological agent for crohn\u2019s disease in a liver transplant patient.","volume":"14","author":"Peverelle","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R106-20260217","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ecco-jcc\/jjab025","article-title":"Systematic review and meta-analysis of outcomes after ileal pouch-anal anastomosis in primary sclerosing cholangitis and ulcerative colitis.","volume":"15","author":"Barnes","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R107-20260217","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1016\/j.cgh.2021.02.006","article-title":"Primary sclerosing cholangitis-associated pouchitis: a distinct clinical phenotype.","volume":"20","author":"Quinn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R108-20260217","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/apt.14393","article-title":"Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.","volume":"47","author":"Nordenvall","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R109-20260217","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ecco-jcc\/jjac190.0010","article-title":"Proctocolectomy with permanent ileostomy is associated with better transplant-free survival in patients with primary sclerosing cholangitis: a retrospective cohort study.","volume":"17","author":"Mol","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R110-20260217","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3748\/wjg.v23.i18.3214","article-title":"Inflammatory bowel disease in liver transplanted patients.","volume":"23","author":"Filipec Kanizaj","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R111-20260217","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.3748\/wjg.v20.i13.3525","article-title":"Clinical management of inflammatory bowel disease in the organ recipient.","volume":"20","author":"Indriolo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R112-20260217","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2013.163","article-title":"Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R113-20260217","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/SLA.0000000000006041","article-title":"Ileal pouch-anal anastomosis in primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD): long-term pouch and liver transplant outcomes.","volume":"278","author":"Maspero","year":"2023","journal-title":"Ann Surg"},{"key":"R114-20260217","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.14828","article-title":"The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis.","volume":"48","author":"Trivedi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R115-20260217","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jss.2009.07.013","article-title":"Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses.","volume":"167","author":"Kuper","year":"2011","journal-title":"J Surg Res"},{"key":"R116-20260217","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"Annual report of the european liver transplant registry (ELTR)\u201450-year evolution of liver transplantation.","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"key":"R117-20260217","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jhep.2023.08.031","article-title":"Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis\u2014a propensity score-matched intention-to-treat analysis.","volume":"80","author":"Aberg","year":"2024","journal-title":"J Hepatol"},{"key":"R118-20260217","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2012.12.027","article-title":"Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.","volume":"11","author":"Jorgensen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R119-20260217","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2010.235408","article-title":"Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?","volume":"60","author":"Marelli","year":"2011","journal-title":"Gut"},{"key":"R120-20260217","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ibd.20087","article-title":"Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients.","volume":"13","author":"Verdonk","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R121-20260217","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"},{"key":"R122-20260217","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0039-6060(05)80026-1","article-title":"Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation.","volume":"118","author":"Knechtle","year":"1995","journal-title":"Surgery"},{"key":"R123-20260217","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.1840220213","article-title":"Liver transplantation for sclerosing cholangitis.","volume":"22","author":"Narumi","year":"1995","journal-title":"Hepatology"},{"key":"R124-20260217","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000658-199705000-00004","article-title":"Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.","volume":"225","author":"Goss","year":"1997","journal-title":"Ann Surg"},{"key":"R125-20260217","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00007890-199802150-00017","article-title":"Clinical course and management of inflammatory bowel disease after liver transplantation.","volume":"65","author":"Befeler","year":"1998","journal-title":"Transplantation"},{"key":"R126-20260217","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/jhep.2002.30695","article-title":"Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.","volume":"35","author":"Dvorchik","year":"2002","journal-title":"Hepatology"},{"key":"R127-20260217","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2036.2003.01613.x","article-title":"Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens.","volume":"18","author":"Haagsma","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R128-20260217","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s10350-004-7291-9","article-title":"Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis.","volume":"46","author":"MacLean","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"R129-20260217","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00042737-200306000-00013","article-title":"Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis.","volume":"15","author":"van de Vrie","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R130-20260217","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/00042737-200512000-00018","article-title":"The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation.","volume":"17","author":"Ho","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R131-20260217","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/lt.21077","article-title":"Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis.","volume":"13","author":"Cholongitas","year":"2007","journal-title":"Liver Transpl"},{"key":"R132-20260217","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.transproceed.2009.03.027","article-title":"Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis.","volume":"41","author":"Bosso","year":"2009","journal-title":"Transplant Proc"},{"key":"R133-20260217","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1155\/2010\/830291","article-title":"The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience.","volume":"24","author":"Moncrief","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"R134-20260217","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.transproceed.2012.07.098","article-title":"Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience.","volume":"44","author":"Gelley","year":"2012","journal-title":"Transplant Proc"},{"key":"R135-20260217","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2036.2012.05067.x","article-title":"The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis.","volume":"35","author":"Navaneethan","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R136-20260217","doi-asserted-by":"crossref","first-page":"510","DOI":"10.6002\/ect.2013.0051","article-title":"Survival without biliary complications after liver transplant for primary sclerosing cholangitis.","volume":"11","author":"Mogl","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"R137-20260217","first-page":"434","article-title":"The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease.","volume":"9","author":"Mosli","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R138-20260217","doi-asserted-by":"crossref","first-page":"e0135807","DOI":"10.1371\/journal.pone.0135807","article-title":"Solid organ transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort.","volume":"10","author":"Schnitzler","year":"2015","journal-title":"PLoS One"},{"key":"R139-20260217","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/MIB.0000000000001105","article-title":"Clinical course of ulcerative colitis after liver transplantation in patients with concomitant primary sclerosing cholangitis and ulcerative colitis.","volume":"23","author":"Fattahi","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R140-20260217","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ibd\/izz325","article-title":"Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes.","volume":"26","author":"Peverelle","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R141-20260217","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.dld.2020.09.011","article-title":"Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study.","volume":"53","author":"Ribaldone","year":"2021","journal-title":"Dig Liver Dis"},{"key":"R142-20260217","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.TP.0000058744.34965.38","article-title":"Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.","volume":"75","author":"Vera","year":"2003","journal-title":"Transplantation"},{"key":"R143-20260217","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1600-6143.2006.01333.x","article-title":"Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease.","volume":"6","author":"Verdonk","year":"2006","journal-title":"Am J Transplant"},{"key":"R144-20260217","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/lt.22320","article-title":"Pediatric liver transplantation for primary sclerosing cholangitis.","volume":"17","author":"Miloh","year":"2011","journal-title":"Liver Transpl"},{"key":"R145-20260217","first-page":"16","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation - The Hungarian experience.","volume":"6","author":"Gelley","year":"2014","journal-title":"Interv Med Appl Sci"},{"key":"R146-20260217","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","article-title":"Risk factors for recurrent primary sclerosing cholangitis after liver transplantation.","volume":"63","author":"Ravikumar","year":"2015","journal-title":"J Hepatol"},{"key":"R147-20260217","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/TXD.0000000000000751","article-title":"Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience.","volume":"3","author":"Ueda","year":"2017","journal-title":"Transplant Direct"},{"key":"R148-20260217","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3748\/wjg.v24.i43.4939","article-title":"Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease.","volume":"24","author":"Bajer","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R149-20260217","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.dld.2020.02.006","article-title":"Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?","volume":"52","author":"Dekkers","year":"2020","journal-title":"Dig Liver Dis"},{"key":"R150-20260217","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0002-9610(98)00141-X","article-title":"Colon carcinoma in patients undergoing liver transplantation.","volume":"176","author":"Fabia","year":"1998","journal-title":"Am J Surg"},{"key":"R151-20260217","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.transproceed.2010.02.016","article-title":"Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients.","volume":"42","author":"Barrera-Pulido","year":"2010","journal-title":"Transplant Proc"},{"key":"R152-20260217","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease.","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R153-20260217","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/gast.1996.v110.pm8566577","article-title":"Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis.","volume":"110","author":"Brentnall","year":"1996","journal-title":"Gastroenterology"},{"key":"R154-20260217","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.510270308","article-title":"Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.","volume":"27","author":"Loftus","year":"1998","journal-title":"Hepatology"},{"key":"R155-20260217","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/ibd\/izx056","article-title":"Reviewing the risk of colorectal cancer in inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.","volume":"24","author":"Rao","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R156-20260217","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/lt.23741","article-title":"Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.","volume":"19","author":"Singh","year":"2013","journal-title":"Liver Transpl"},{"key":"R157-20260217","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.13894","article-title":"Systematic review: recurrent autoimmune liver diseases after liver transplantation.","volume":"45","author":"Montano-Loza","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R158-20260217","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.15148","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.","volume":"49","author":"Steenstraten","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R159-20260217","doi-asserted-by":"crossref","first-page":"100599","DOI":"10.1016\/j.jhepr.2022.100599","article-title":"Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study.","volume":"4","author":"Visseren","year":"2022","journal-title":"JHEP Rep"},{"key":"R160-20260217","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-0041-1730950","article-title":"Recurrent primary sclerosing cholangitis: current understanding, management, and future directions.","volume":"41","author":"Leung","year":"2021","journal-title":"Semin Liver Dis"},{"key":"R161-20260217","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a nordic multicentre study.","volume":"53","author":"Lindstrom","year":"2018","journal-title":"Scand J Gastroenterol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:00:44Z","timestamp":1771333244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":161,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005607","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}